-
Announcement of the State Food and Drug Administration on Revising the Instructions for Propylthiouracil Preparations (No. 103 of 2021)
Time of Update: 2021-11-14
The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, and in accordance with the requirements for the revision of the propylthiouracil preparation instructions (see attachment), before November 22, 2021 Report to the provincial drug supervision and administration department for the record .
-
Overview of the application of prodrug technology in pulmonary inhalation preparations
Time of Update: 2021-11-14
By SharoCompared with systemic administration such as oral or injection, lung inhaled drugs directly enter the respiratory tract through a special drug delivery device to exert a therapeutic effect, and has shown obvious advantages in the treatment of asthma and chronic obstructive pulmonary disease .
-
Announcement of the State Food and Drug Administration on the conversion of compound Banlangen Granules into over-the-counter drugs (No. 58 of 2021)
Time of Update: 2021-11-14
The list of varieties (Annex 1) and the template of non-prescription drug instructions (Annex 2) are released together .
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
-
The place will carry out the purchase of low-value consumables with a quantity, and the product decline may be very substantial
Time of Update: 2021-11-14
The notice pointed out that after the implementation of the Internet, in addition to first aid and other clinical needs, low-value medical consumables and test reagents used by public medical and health institutions in the city must be purchased on the procurement platform.
-
Genxi Biotech will announce the results of preclinical research on the treatment of B-cell malignant tumors based on the CD19/CD7 dual-targeting allogeneic CAR-T candidate product (GC502) developed by TruUCAR at the 63rd ASH Annual Meeting
Time of Update: 2021-11-14
Suzhou, Shanghai, China and Palo Alto, California, USA November 4, 2021/PRNewswire/ - Genxi Biotech Group (NASDAQ: GRCL; referred to as "Genxi Bio") is committed to A global clinical-stage biopharmace
-
The National Medical Insurance Bureau issued the national procurement renewal document: no "only bargaining, no quantity"!
Time of Update: 2021-11-14
In addition, in response to previous penalties for winning bids for failing to supply the agreed procurement volume in accordance with the agreement, the "Notice" also made provisions on "strengthening credit and performance evaluation", "improving supporting policies", and "strengthening performance supervision".
-
Jinghua Pharmaceutical completed the sale of its subsidiary Wannianchang Pharmaceutical's equity
Time of Update: 2021-11-14
On November 4, Jinghua Pharmaceutical issued an announcement stating that it had recently completed the sale of equity in its subsidiary Wannianchang Pharmaceutical .
The equity transfer transaction has been completed, and Jinghua Pharmaceutical no longer holds the equity of Wannianchang Pharmaceutical .
-
"4+7" Cardiovascular Drug Terminal Market Changes
Time of Update: 2021-11-14
Figure 4 The market share and price trend of losartan designated product regulations in the sample hospital market (2017-2021H1)Based on the PDB domestic sample hospital market data, the market share and price changes of the four product specifications of Irbesartan from 2017 to the first half of 2021 are calculated separately.
-
ADC drugs enter the hot spot of industry attention, and domestic research and development is booming
Time of Update: 2021-11-14
7 billion yuan, invest in the construction of the company’s Hangzhou biopharmaceutical project, engage in the research and development of anti-tumor ADC drugs, and set up other Subsidiaries and other industries .
-
Announcement of the State Food and Drug Administration on the issuance of two supplementary inspection methods for the rosin acid check item in Xiaozhong tablets and the check item of rhubarb glycosides in compound gentian sodium bicarbonate tablets (
Time of Update: 2021-11-14
Supplementary inspection method for rhubarb glycosides inspection items in compound gentian sodium bicarbonate tablets National Medical Products Administration October 12, 2021 National Medical Products Administration 2021 Announcement No.
-
Johnson & Johnson, U.S., etc. are all developing the first FcRn-targeted new drug. When will it arrive?
Time of Update: 2021-11-14
In addition, another important research direction in this field is to develop drugs to inhibit the binding of endogenous FcRn and IgG, thereby treating autoimmune diseases driven by autoantibody .
-
The pattern of the pharmaceutical industry will see new changes, and a large number of pharmaceutical companies may be eliminated
Time of Update: 2021-11-14
It will be of great significance in improving the development quality of China's pharmaceutical industry, ensuring the safety and effectiveness of drugs, forcing pharmaceutical companies to innovate in products and management models, promoting the upgrading and structural adjustment of the pharmaceutical industry, and enhancing international competitiveness .
-
The peptide drug market in my country has further expanded, and these companies are worth recommending
Time of Update: 2021-11-14
As a domestic peptide drug company, Sino Bio has always established its brand with innovative peptide drug pharmaceutical research services and peptide product customized production services, based on the large-scale production and sales of raw materials .
-
Announcement of the General Administration of Customs of the State Food and Drug Administration on the addition of Changchun Air Port as a port for drug import (No. 79 of 2021)
Time of Update: 2021-11-14
2. Adding Jilin Provincial Drug Administration as the port drug supervision and management department, which will undertake the specific work of the record of drug imports at Changchun Airport .
Since the date of this announcement, Jilin Provincial Institute of Drug Inspection has begun to undertake the inspection of drugs at Changchun Airport .
-
Merck's "Cetuximab" New Indication Application for Listing
Time of Update: 2021-11-14
At present, cetuximab has been approved for marketing in more than 100 countries around the world, mainly for the treatment of colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN) .
-
Innovative achievements have been transformed into market considerations, and 3 new pharmaceutical stocks have broken!
Time of Update: 2021-11-14
According to statistics, a total of 396 companies have landed on the A-share market in 2020, but none of them broke on the first day of listing, and as of the end of the year, only 22 companies had fallen below the issue price .
-
TOP10 failed clinical studies in October 2021
Time of Update: 2021-11-14
Phase III study of Canakinumab in the treatment of non-small cell lung cancerNovartis announced on October 25 that the IL-1β inhibitor Canakinumab (canakinumab, ACZ885) combined with pembrolizumab plus platinum dual-drug chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) The phase III clinical study (CANOPY-1) failed to achieve the primary endpoints of improving overall survival (OS) and progression-free survival (PFS) .
-
Asia Pacific Pharmaceuticals Mosapride Citrate Granules Obtained Drug Registration Certificate
Time of Update: 2021-11-14
On November 4, Asia-Pacific Pharmaceuticals issued an announcement stating that the company had received the "Drug Registration Certificate" for the chemical mosapride citrate granules approved and issued by the National Medical Products Administration .
No other company has obtained the registration certificate of the drug granules.
-
Shandong: 115 drugs have been transferred out of medical insurance today!
Time of Update: 2021-11-14
Recently, Shandong Province Public Resource Exchange Center issued the "Notice on the province basic medical insurance, industrial injury insurance and maternity insurance drug list additions drugs in 2021 transferred out of work" .
-
The first domestic product! Connoa's TSLP monoclonal antibody is approved for clinical treatment of atopic dermatitis
Time of Update: 2021-11-14
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn November 3, Connoa announced that the CM326 clinical trial application was approved by the Food and Drug Administration for the treatment of atopic dermatitis .
CM326 is the first domestic TSLP targeting antibody in China and the third in the world to be approved for clinical trial applications .
